Recently, the WHO and IARC released the latest World Cancer Report, which provides a comprehensive overview of the global burden of increasing cancer-incidence, risk factors, and biological processes of cancer and prevention measures.

Cancer has already become the second leading cause of death globally, while the number of cases still revealed with an increasing trend year by year. The World Health Organization (WHO) estimates that the number of cancer cases worldwide is likely to increase by 60% more in the next 20 years.

Doxorubicin (DOX) has been used as a first-line treatment for cancer and is a non-negligible revenue player for the pharmaceutical industry. Because of its toxicity and bright red appearance, Doxorubicin has long had a frightening nickname: Red Devil. In addition to most chemotherapy antibiotics’ common side effects such as nausea, vomiting, canker sores, and hair loss, DOX can also cause acute and chronic heart toxicity, which can be almost fatal.
Previous studies have shown that doxorubicin (DOX) blocks the autophagic flux in cardiomyocytes by inhibiting lysosome acidification. The V-ATPase pump maintains the acidic pH of lysosomes. However, DOX treatment also significantly depletes the NAD+ levels in cardiomyocytes.
Therefore, the study conducted by The University of Western Ontario investigated NMN’s potential in preventing DOX-induced cardiotoxicity. DOX-induced cell injury and altered the lysosomal pH of H9c2 cells, an in vitro model of cardiomyocytes. And NMN attenuated these effects of DOX. Furthermore, NMN prevented the DOX-induced hyperacetylation of the V-ATPase subunit ATP6V0d1, a critical protein involved in V-ATPase activity maintenance.

In summary, NMN protects cardiomyocytes from DOX-induced toxicity by maintaining the pH of lysosomes. Thus, NMN holds potential in combating the harmful impacts of Doxorubicin on the heart.
This research is undoubtedly another great discovery in the field of NMN research. Because DOX is commonly used to treat many types of cancer, many patients who survive the battles with their disease get heart illness after treatment, impacting their daily life quality. And this paper strengthens our faith that with more in-depth and comprehensive research on NAD+ and NMN, NMN will help the people he relies on to achieve a better life and future.

Effepharm has already embedded the concept of pharmaceutical R&D during its product development process. And as the world’s largest manufacturer of NMN raw materials, which has taken up 70% worldwide market share, Effepharm conducted a series of safety and efficacy studies. Effepharm has long cooperated with top pharmaceutical companies and world-class pharmaceutical research institutes and devoted to studying the function of NMN in the field of medicine.
Effepharm is also the only NMN raw material manufacturer in the world to conduct clinical trials. It has launched a multicenter, randomized, double-blind, parallel design, placebo-controlled study to evaluate the efficacy and safety of NMN, which provide valuable information for the NMN R&D.

All these efforts have made the UTHEVER® been trusted and praised by worldwide clients.
And by choosing Effepharm, you are promised to serve with the world-best NMN raw material.


Nima Nalin. Nicotinamide mononucleotide imparts protection against Doxorubicin-induced cardiotoxicity by maintaining lysosomal acidification. Master thesis: The University of Western Ontario; 2020., Available from